Math-free guides for glycerin and allergens at variable subcutaneous injection volumes

Grier, Thomas J.; Converse, Lorie M.; Rekkerth, Donna J.; Renahan, Kevin E.

doi:10.1016/j.anai.2016.02.015

Cited by 3 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…anticipated ability to deliver adequate allergen doses. 69 However, it should be noted that none of the tree mixes are standardized and the major allergens have only been characterized for birch and mountain cedar. 70,71 The work by Turkeltaub 70 demonstrates that even the most potent tree allergen extracts are less than 10,000 BAU/mL, which is much lower than grasses (Timothy grass is 100,000 BAU/mL).…”

Section: Clinical Trial Concepts Workgroup 1: Scit Vs Slitmentioning

confidence: 99%

Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy—An NIAID/AHRQ Workshop

Wheatley

Wood

Nadeau

et al. 2019

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Diseases organized a workshop to develop trial concepts that could improve the use and effectiveness of aeroallergen immunotherapy (AAIT). Expert groups were formed to accomplish the following tasks: (1) propose a study design to compare the effectiveness and safety of subcutaneous versus sublingual AAIT; (2) propose a study design to compare the effectiveness and safety of AAIT by using 1 or a few allergens versus all or most allergens to which a patient is sensitized; (3) propose a study design to determine whether AAIT can alter the progression of childhood allergic airways disease; and (4) propose a study design to determine the optimal dose and duration of AAIT to achieve maximal effectiveness with acceptable safety. Study designs were presented by the workgroups, extensively discussed at the workshop, and revised for this report. The proposed trials would be of long duration and require large highly characterized patient populations. Scientific caveats and feasibility matters are discussed. These concepts are intended to help the development of clinical trials that can address some of the major questions related to the practice of AAIT for the management and prevention of allergic airways disease.

show abstract

Section: Clinical Trial Concepts Workgroup 1: Scit Vs Slitmentioning

confidence: 99%

Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy—An NIAID/AHRQ Workshop

Wheatley

Wood

Nadeau

et al. 2019

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

show abstract

Allergen Immunotherapy in Young Children

Phomakay

Tankersley

2022

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Current concepts in optimized construction of allergen immunotherapy vaccines: Practical implications

Tankersley¹

2022

allergy asthma proc

View full text Add to dashboard Cite

The administration of allergen immunotherapy, since its inception more than 100 years ago, remains a therapy unique to the field of allergy and immunology. The practicing, board-certified allergist is best equipped to evaluate and manage the allergic patient. The safety and efficacy of allergen immunotherapy is well established, and both are discussed in specific chapters in this primer. The practical application of each of these within the confines of the shot room (i.e., the places or places in the medical facility where injections are administered in the allergy clinic) are addressed in this chapter. In addition, practical suggestions are provided to enhance patient adherence with allergen immunotherapy while maximizing the practice management model as services are executed. The successful implementation of each of these areas (safety, efficacy, adherence, and profit margin) will allow the practicing allergist to optimize the clinical delivery of allergen immunotherapy within communities and to the patients being served. The optimization of allergen immunotherapy (AIT) depends on four specific defining factors: 1) safety; 2) efficacy; 3) adherence; and 4) profit margin. Identifying specific problems which could impede each of these four factors is necessary to ensure the success of AIT. The practical implications of these core concepts as they apply to AIT will be explored in this chapter.

show abstract

Math-free guides for glycerin and allergens at variable subcutaneous injection volumes

Cited by 3 publications

References 20 publications

Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy—An NIAID/AHRQ Workshop

Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy—An NIAID/AHRQ Workshop

Allergen Immunotherapy in Young Children

Current concepts in optimized construction of allergen immunotherapy vaccines: Practical implications

Contact Info

Product

Resources

About